Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.

J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.

PMID:
31085679
2.

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.

Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast CC, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'Agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM; CureGN Consortium.

Am J Kidney Dis. 2019 Feb;73(2):218-229. doi: 10.1053/j.ajkd.2018.07.020. Epub 2018 Nov 9.

PMID:
30420158
3.

Alterations of peritoneal transport characteristics in dialysis patients with ultrafiltration failure: tissue and capillary components.

Stachowska-Pietka J, Poleszczuk J, Flessner MF, Lindholm B, Waniewski J.

Nephrol Dial Transplant. 2019 May 1;34(5):864-870. doi: 10.1093/ndt/gfy313.

PMID:
30403818
4.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD.

Kidney Int Rep. 2018 Jan 6;3(3):619-624. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May.

5.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt Pkd Investigators.

Curr Hypertens Rev. 2018;14(1):39-47. doi: 10.2174/1573402114666180322110209.

6.

Relation of uric acid level to rapid kidney function decline and development of kidney disease: The Jackson Heart Study.

Mwasongwe SE, Fülöp T, Katz R, Musani SK, Sims M, Correa A, Flessner MF, Young BA.

J Clin Hypertens (Greenwich). 2018 Apr;20(4):775-783. doi: 10.1111/jch.13239. Epub 2018 Feb 16.

7.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

8.

Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.

9.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

10.

Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.

Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE; HALT PKD Investigators.

Curr Hypertens Rev. 2017;13(2):109-120. doi: 10.2174/1573402113666170427142815.

11.

Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.

Shen C, Landsittel D, Irazabal MV, Yu AS, Chapman AB, Mrug M, Grantham JJ, Bae KT, Bennett WM, Flessner MF, Torres VE; CRISP Investigators.

Am J Kidney Dis. 2017 Mar;69(3):482-484. doi: 10.1053/j.ajkd.2016.10.021. Epub 2016 Dec 24. No abstract available.

12.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF.

Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

13.

Pharmacokinetic problems in peritoneal drug administration: an update after 20 years.

Flessner MF.

Pleura Peritoneum. 2016 Dec 1;1(4):183-191. doi: 10.1515/pp-2016-0022. Epub 2016 Dec 20. Review.

14.

Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease.

Kim Y, Bae SK, Cheng T, Tao C, Ge Y, Chapman AB, Torres VE, Yu AS, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT.

Phys Med Biol. 2016 Nov 21;61(22):7864-7880. Epub 2016 Oct 25.

15.

Glomerular Diseases: Registries and Clinical Trials.

Moxey-Mims MM, Flessner MF, Holzman L, Kaskel F, Sedor JR, Smoyer WE, Thompson AM, Yao L.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2234-2243. Epub 2016 Sep 26.

16.

African Ancestry-Specific Alleles and Kidney Disease Risk in Hispanics/Latinos.

Kramer HJ, Stilp AM, Laurie CC, Reiner AP, Lash J, Daviglus ML, Rosas SE, Ricardo AC, Tayo BO, Flessner MF, Kerr KF, Peralta C, Durazo-Arvizu R, Conomos M, Thornton T, Rotter J, Taylor KD, Cai J, Eckfeldt J, Chen H, Papanicolau G, Franceschini N.

J Am Soc Nephrol. 2017 Mar;28(3):915-922. doi: 10.1681/ASN.2016030357. Epub 2016 Sep 20.

17.

Trans-ethnic Fine Mapping Highlights Kidney-Function Genes Linked to Salt Sensitivity.

Mahajan A, Rodan AR, Le TH, Gaulton KJ, Haessler J, Stilp AM, Kamatani Y, Zhu G, Sofer T, Puri S, Schellinger JN, Chu PL, Cechova S, van Zuydam N; SUMMIT Consortium; BioBank Japan Project, Arnlov J, Flessner MF, Giedraitis V, Heath AC, Kubo M, Larsson A, Lindgren CM, Madden PAF, Montgomery GW, Papanicolaou GJ, Reiner AP, Sundström J, Thornton TA, Lind L, Ingelsson E, Cai J, Martin NG, Kooperberg C, Matsuda K, Whitfield JB, Okada Y, Laurie CC, Morris AP, Franceschini N.

Am J Hum Genet. 2016 Sep 1;99(3):636-646. doi: 10.1016/j.ajhg.2016.07.012.

18.

Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.

Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE; HALT Investigators.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1857-1865. doi: 10.1093/ndt/gfw294.

19.

Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative.

Dember LM, Archdeacon P, Krishnan M, Lacson E Jr, Ling SM, Roy-Chaudhury P, Smith KA, Flessner MF.

J Am Soc Nephrol. 2016 Oct;27(10):2955-2963. Epub 2016 Jul 11. Review.

20.

Smoking patterns and chronic kidney disease in US Hispanics: Hispanic Community Health Study/Study of Latinos.

Franceschini N, Deng Y, Flessner MF, Eckfeldt JH, Kramer HJ, Lash JP, Lee DJ, Melamed ML, Moncrieft AE, Ricardo AC, Rosas SE, Kaplan RC, Raij L, Cai J.

Nephrol Dial Transplant. 2016 Oct;31(10):1670-6. doi: 10.1093/ndt/gfw210. Epub 2016 Jun 2.

21.

Concomitant bidirectional transport during peritoneal dialysis can be explained by a structured interstitium.

Stachowska-Pietka J, Waniewski J, Flessner MF, Lindholm B.

Am J Physiol Heart Circ Physiol. 2016 Jun 1;310(11):H1501-11. doi: 10.1152/ajpheart.00925.2014. Epub 2016 Mar 4.

22.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

23.

Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease.

Kim Y, Ge Y, Tao C, Zhu J, Chapman AB, Torres VE, Yu AS, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2016 Apr 7;11(4):576-84. doi: 10.2215/CJN.08300815. Epub 2016 Jan 21.

24.

Prevalence and Correlates of CKD in Hispanics/Latinos in the United States.

Ricardo AC, Flessner MF, Eckfeldt JH, Eggers PW, Franceschini N, Go AS, Gotman NM, Kramer HJ, Kusek JW, Loehr LR, Melamed ML, Peralta CA, Raij L, Rosas SE, Talavera GA, Lash JP.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1757-66. doi: 10.2215/CJN.02020215. Epub 2015 Sep 28.

25.

Closeout of the HALT-PKD trials.

Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC.

Contemp Clin Trials. 2015 Sep;44:48-55. doi: 10.1016/j.cct.2015.07.017. Epub 2015 Jul 29.

26.

Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA.

J Am Soc Nephrol. 2015 Oct;26(10):2328-39. doi: 10.1681/ASN.2015020117. Epub 2015 May 12. Review.

27.

An unusual cause of acute kidney injury due to oxalate nephropathy in systemic scleroderma.

Mascio HM, Joya CA, Plasse RA, Baker TP, Flessner MF, Nee R.

Clin Nephrol. 2015 Aug;84(2):111-5. doi: 10.5414/CN108406.

PMID:
25500295
28.

Blood pressure in early autosomal dominant polycystic kidney disease.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2255-66. doi: 10.1056/NEJMoa1402685. Epub 2014 Nov 15.

29.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

30.

Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative.

Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL; Kidney Health Initiative.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):159-64. doi: 10.2215/CJN.05630614. Epub 2014 Sep 4.

31.

Filling the holes in cystic kidney disease research.

Guay-Woodford LM, Henske E, Igarashi P, Perrone RD, Reed-Gitomer B, Somlo S, Torres VE, Ketchum CJ, Star RA, Flessner MF, Rasooly RS.

Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1799-801. doi: 10.2215/CJN.03410414. Epub 2014 Jun 5. Review.

32.

Glomerular disease: looking beyond pathology.

Wiggins RC, Alpers CE, Holzman LB, He JC, Salant DJ, Chugh SS, Natarajan R, Trachtman H, Brasile L, Star RA, Rys-Sikora KE, Moxey-Mims MM, Flessner MF; Kidney Research National Dialogue.

Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1138-40. doi: 10.2215/CJN.01450214. Epub 2014 Apr 3.

33.

Novel methodology to evaluate renal cysts in polycystic kidney disease.

Bae KT, Sun H, Lee JG, Bae K, Wang J, Tao C, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease.

Am J Nephrol. 2014;39(3):210-7. doi: 10.1159/000358604. Epub 2014 Feb 22.

34.

Improving CKD therapies and care: a National Dialogue.

Kaskel F, Batlle D, Beddhu S, Daugirdas J, Feldman H, Ferris M, Fine L, Freedman BI, Kimmel PL, Flessner MF, Star RA; Kidney Research National Dialogue (KRND).

Clin J Am Soc Nephrol. 2014 Apr;9(4):815-7. doi: 10.2215/CJN.12631213. Epub 2014 Feb 7.

35.

Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.

Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW; HALT-PKD Study.

Am J Kidney Dis. 2014 Feb;63(2):214-26. doi: 10.1053/j.ajkd.2013.08.017. Epub 2013 Nov 1.

36.

Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease.

Bae KT, Tao C, Wang J, Kaya D, Wu Z, Bae JT, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Am J Nephrol. 2013;38(4):333-41. doi: 10.1159/000355375. Epub 2013 Oct 5.

37.

In reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'.

St Peter WL, Weinhandl ED, Flessner MF.

Am J Kidney Dis. 2013 Sep;62(3):642-3. doi: 10.1053/j.ajkd.2013.06.009. No abstract available.

PMID:
23972059
38.

Diabetic nephropathy: a national dialogue.

Breyer MD, Coffman TM, Flessner MF, Fried LF, Harris RC, Ketchum CJ, Kretzler M, Nelson RG, Sedor JR, Susztak K; Kidney Research National Dialogue (KRND).

Clin J Am Soc Nephrol. 2013 Sep;8(9):1603-5. doi: 10.2215/CJN.03640413. Epub 2013 Jun 20.

39.

Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease.

Bae K, Park B, Sun H, Wang J, Tao C, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2013 Jul;8(7):1089-97. doi: 10.2215/CJN.10561012. Epub 2013 Mar 21.

40.

Sitagliptin--another option for managing type 2 diabetes in dialysis patients?

St Peter WL, Weinhandl ED, Flessner MF.

Am J Kidney Dis. 2013 Apr;61(4):532-5. doi: 10.1053/j.ajkd.2013.01.004. No abstract available.

PMID:
23497767
41.

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.

Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP.

Am J Kidney Dis. 2013 Mar;61(3):420-9. doi: 10.1053/j.ajkd.2012.08.038. Epub 2012 Oct 22.

42.

Solid-organ transplantation in older adults: current status and future research.

Abecassis M, Bridges ND, Clancy CJ, Dew MA, Eldadah B, Englesbe MJ, Flessner MF, Frank JC, Friedewald J, Gill J, Gries C, Halter JB, Hartmann EL, Hazzard WR, Horne FM, Hosenpud J, Jacobson P, Kasiske BL, Lake J, Loomba R, Malani PN, Moore TM, Murray A, Nguyen MH, Powe NR, Reese PP, Reynolds H, Samaniego MD, Schmader KE, Segev DL, Shah AS, Singer LG, Sosa JA, Stewart ZA, Tan JC, Williams WW, Zaas DW, High KP.

Am J Transplant. 2012 Oct;12(10):2608-22. doi: 10.1111/j.1600-6143.2012.04245.x. Epub 2012 Sep 7.

43.

Sleep-disordered breathing symptoms among African-Americans in the Jackson Heart Study.

Fülöp T, Hickson DA, Wyatt SB, Bhagat R, Rack M, Gowdy O Jr, Flessner MF, Taylor HA.

Sleep Med. 2012 Sep;13(8):1039-49. doi: 10.1016/j.sleep.2012.06.005. Epub 2012 Jul 25.

44.

Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: a spatially distributed approach.

Stachowska-Pietka J, Waniewski J, Flessner MF, Lindholm B.

Am J Physiol Renal Physiol. 2012 May 15;302(10):F1331-41. doi: 10.1152/ajprenal.00301.2011. Epub 2012 Feb 1.

45.

Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects.

Wilmot B, Voruganti VS, Chang YP, Fu Y, Chen Z, Taylor HA, Wilson JG, Gipson T, Shah VO, Umans JG, Flessner MF, Hitzemann R, Shuldiner AR, Comuzzie AG, McWeeney S, Zager PG, Maccluer JW, Cole SA, Cohen DM.

Physiol Genomics. 2012 Feb 13;44(3):220-8. doi: 10.1152/physiolgenomics.00153.2011. Epub 2011 Dec 20.

46.

Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites.

Textor SC, Gloviczki ML, Flessner MF, Calhoun DA, Glockner J, Grande JP, McKusick MA, Cha SS, Lerman LO.

Am J Kidney Dis. 2012 Feb;59(2):229-37. doi: 10.1053/j.ajkd.2011.09.023. Epub 2011 Nov 29.

47.

Association between circulating specific leukocyte types and incident chronic kidney disease: the Atherosclerosis Risk in Communities (ARIC) study.

Tian N, Penman AD, Manning RD Jr, Flessner MF, Mawson AR.

J Am Soc Hypertens. 2012 Mar-Apr;6(2):100-8. doi: 10.1016/j.jash.2011.10.001. Epub 2011 Nov 3.

48.

Genetic association for renal traits among participants of African ancestry reveals new loci for renal function.

Liu CT, Garnaas MK, Tin A, Kottgen A, Franceschini N, Peralta CA, de Boer IH, Lu X, Atkinson E, Ding J, Nalls M, Shriner D, Coresh J, Kutlar A, Bibbins-Domingo K, Siscovick D, Akylbekova E, Wyatt S, Astor B, Mychaleckjy J, Li M, Reilly MP, Townsend RR, Adeyemo A, Zonderman AB, de Andrade M, Turner ST, Mosley TH, Harris TB; CKDGen Consortium, Rotimi CN, Liu Y, Kardia SL, Evans MK, Shlipak MG, Kramer H, Flessner MF, Dreisbach AW, Goessling W, Cupples LA, Kao WL, Fox CS.

PLoS Genet. 2011 Sep;7(9):e1002264. doi: 10.1371/journal.pgen.1002264. Epub 2011 Sep 8.

49.

Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele.

Tin A, Woodward OM, Kao WH, Liu CT, Lu X, Nalls MA, Shriner D, Semmo M, Akylbekova EL, Wyatt SB, Hwang SJ, Yang Q, Zonderman AB, Adeyemo AA, Palmer C, Meng Y, Reilly M, Shlipak MG, Siscovick D, Evans MK, Rotimi CN, Flessner MF, Köttgen M, Cupples LA, Fox CS, Köttgen A; CARe and CHARGE Consortia.

Hum Mol Genet. 2011 Oct 15;20(20):4056-68. doi: 10.1093/hmg/ddr307. Epub 2011 Jul 18.

50.

Foreign-body response to sterile catheters is variable over 20 weeks.

Flessner MF, Li X, Potter R, He Z.

Adv Perit Dial. 2010;26:101-4.

PMID:
21348390

Supplemental Content

Loading ...
Support Center